Multicenter, Open-Label, Single Arm Phase II Clinical Trial of Dasatinib in the Treatment of Systemic Mastocytosis.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Systemic mastocytosis
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 24 Mar 2012 Actual initiation date (22 Jan 2010) added as reported by European Clinical Trials Database.
- 24 Mar 2012 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.